NASDAQ · IMTXW
Healthcare · Biotechnology
$0.00
Down-$0.00 (-88.46%)
Updated Sep 19, 2026, 4:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IMTXW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning IMTXW.
IMTXW research
Company profile and research snapshot.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Nov 8, 2024
Immatics announced positive clinical data for its TCR-T therapy candidates targeting PRAME, a protein frequently expressed in solid cancers. The data showed deep and durable responses in heavily pretreated patients, supporting the advancement of these therapies into late-stage development.
GlobeNewswire Inc. · Oct 11, 2024
Immatics, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 16,250,000 ordinary shares at $9.25 per share. The offering is expected to close on October 15, 2024.
GlobeNewswire Inc. · Oct 4, 2024
Immatics, a clinical-stage biopharmaceutical company, announced upcoming oral and poster presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024. The presentations will focus on their TCR-T therapies targeting the PRAME antigen for the treatment of solid cancers.
GlobeNewswire Inc. · Aug 13, 2024
Immatics reported positive clinical data for its ACTengine® IMA203 targeting PRAME in metastatic melanoma patients, with a 55% confirmed objective response rate and a favorable tolerability profile. The company also announced upcoming data presentations for its TCR Bispecifics pipeline, including IMA401 and IMA402, and the appointment of Alise Reicin, M.D. to its Board of Directors.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMTXW.
No results
No recent SID articles mention IMTXW.
